Aequus Pharmaceuticals Inc. (TSXV: AQS)

Market Cap	663.17K
Revenue (ttm)	413.17K
Net Income (ttm)	-2.68M
Shares Out	132.63M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,000
Average Volume	60,629
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0150
52-Week Range	0.0050 - 0.0400
Beta	-0.02
RSI	36.73
Earnings Date	May 1, 2025

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 12
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: AQS

Financial Performance

In 2023, Aequus Pharmaceuticals's revenue was 254,896, a decrease of -81.53% compared to the previous year's 1.38 million. Losses were -2.96 million, -7.64% less than in 2022.